摘要
通过建立慢性豚鼠哮喘模型,研究重组人磷脂酶D2(rhPLD2)干预慢性哮喘豚鼠血清中糖基化磷脂酰肌醇特异性磷脂酶D(GPI-PLD)含量的变化,探寻可能的机制.以rhPLD2干预慢性哮喘豚鼠,用TX-114分相法检测豚鼠血清中GPI-PLD酶活性.与正常状态豚鼠相比较,慢性哮喘状态豚鼠其血清中GPI-PLD酶活性显著升高.但以rhPLD2及地塞米松干预慢性哮喘豚鼠后,该指标显著下降.rhPLD2可通过抑制其血清中GPI-PLD酶活性表达,来抑制哮喘发生过程中的炎症反应.
The effect of recombinant human phospholipase D2 （rhPLD2） in vivo was investigated on the secretion of serum glycosyl phosphafidylinositol-specific phospholipase D （GPI-PLD） in guinea pigs of chronic asthma. After treating the guinea pigs attacked by chronic asthma with rhPLD2, the GPI-PLD activity detection was carried out by phase separation of human placental alkaline phosphatase in Triton X-114. Compared with the healthy guinea pigs（NS group）, the serum GPI-PLD in the guinea pigs of chronic asthma are much higher than that of control groups, P≤0.01. Our results showed that rhPLD2 could significantly reduce the secretion of GPI-PLD when the guinea pigs were attacked by chronic asthma.
出处
《中国生物化学与分子生物学报》
CAS
CSCD
北大核心
2007年第2期116-121,共6页
Chinese Journal of Biochemistry and Molecular Biology
基金
福建省科技攻关重点项目(No2004Y010)
福建省产业技术研究开发项目(No200504)~~
